製藥業

藥品現代流通研究報告 : = 中國藥品現代市場體系的研究與設計 / by: (Language materials, printed)

中國大陸中藥製劑市場競爭分析 / by: (Language materials, printed)

亞洲藥品市場的商機探討 / by: (Language materials, printed)

生物相似性藥品發展現況及趨勢 / by: (Language materials, printed)

中國大陸醫藥品流通產業 / by: (Language materials, printed)

生技投資聖經 : = 看懂台灣生技股的第一本書 / by: (Language materials, printed)

藥物設計策略 / by: (Language materials, printed)

我國生醫產業與中國大陸醫藥流通產業合作策略研究 / by: (Language materials, printed)

馬來西亞藥品產業發展現況與前景 / by: (Language materials, printed)

銀髮族優質生活之生技醫藥產品商機探討 / by: (Language materials, printed)

輝瑞守護健康160年 : = 用老經驗,探尋新技術 / by: (Language materials, printed)

生醫新視野 : = 生技產業投資停看聽 / by: (Language materials, printed)

生技投資聖經二部曲 : = 一定要懂的投資策略 / by: (Language materials, printed)

醫藥品上市所衍生智慧財產權爭議之研究 = 以台灣學名藥廠為主 / by: (Electronic resources)

生技新藥產業發展條例廣宣手冊 / by: (Language materials, printed)

謊言之瓶 : = 學名藥奇蹟背後,全球製藥產業鍊興起的內幕、利益與真相 / by: (Language materials, printed)

醫藥幽靈 : = 大藥廠如何干預醫療知識的生產、傳播與消費 / by: (Language materials, printed)

疼痛帝國 : = 薩克勒家族製藥王朝祕史 / by: (Language materials, printed)

藥品帝國 : = 從阿斯匹靈到COVID-19疫苗的人類醫藥壟斷史 / by: (Language materials, printed)

藥命之財 : = 揭露全球製藥產業的漫天藥價與骯髒手法 / by: (Language materials, printed)

生技/製藥產業關鍵原料及組件之商機與發展策略探討 / by: (Language materials, printed)

生技/製藥廠商聯盟及授權標竿案例與價值分析 / by: (Language materials, printed)

藥品再創價值的策略運用與發展趨勢 / by: (Language materials, printed)

抗體應用於檢測及醫療之商機 / by: (Language materials, printed)

臺灣古早藥包 / by: (Language materials, printed)

醫藥產業年鑑 = = Yearbook of pharmaceutical industry 2012 / . 2012 by: (Language materials, printed)

臺灣古早藥包 by: (Electronic resources)

我國生醫產業與中國大陸醫藥流通產業合作策略研究 by: (Electronic resources)

打通東協醫藥市場任督二脈. = 醫療法規與通路布局之解析 = Analysis of the regulation and channel of the ASEAN pharmaceutical industry-Indonesia /. 印尼 by: (Electronic resources)

打通東協醫藥市場任督二脈. = 醫療法規與通路布局之解析 = Analysis of the regulation and channel of the ASEAN pharmaceutical industry-Thailand /. 泰國 by: (Electronic resources)

藥向前行 = Marching forward : the development of pharmaceutical marketing in Taiwan : 臺灣藥品行銷發展 / by: (Electronic resources)